WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010142603) SCREENING FOR COMPOUNDS THAT MODULATE GPR3-MEDIATED BETA-ARRESTIN SIGNALING AND AMYLOID BETA PEPTIDE GENERATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/142603    International Application No.:    PCT/EP2010/057808
Publication Date: 16.12.2010 International Filing Date: 04.06.2010
IPC:
G01N 33/68 (2006.01), A61K 31/7088 (2006.01), C12N 15/11 (2006.01)
Applicants: VIB VZW [BE/BE]; Rijvisschestraat 120 B-9052 Gent (BE) (For All Designated States Except US).
KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D [BE/BE]; Waaistraat 6, bus 5105 B-3000 Leuven (BE) (For All Designated States Except US).
DE STROOPER, Bart [BE/BE]; (BE) (For US Only).
THATHIAH, Amantha [US/BE]; (BE) (For US Only)
Inventors: DE STROOPER, Bart; (BE).
THATHIAH, Amantha; (BE)
Common
Representative:
VIB VZW; Rijvisschestraat 120 B-9052 Gent (BE)
Priority Data:
61/268,054 08.06.2009 US
Title (EN) SCREENING FOR COMPOUNDS THAT MODULATE GPR3-MEDIATED BETA-ARRESTIN SIGNALING AND AMYLOID BETA PEPTIDE GENERATION
(FR) CRIBLAGE DE COMPOSÉS MODULANT LA SIGNALISATION DE LA BÊTA-ARRESTINE INDUITE PAR GPR3 ET LA FORMATION DES PEPTIDES BÊTA-AMYLOÏDES
Abstract: front page image
(EN)The present invention relates to the field of disorders of the peripheral or central nervous system, in particular Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the present invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell, and in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of said disorders.
(FR)La présente invention concerne le domaine des troubles du système nerveux périphérique ou central, en particulier la maladie d'Alzheimer, et leur prévention et/ou leur traitement. En particulier, la présente invention concerne le criblage de composés modulant l'activité de GPR3 et/ou la signalisation de la bêta-arrestine dans une cellule de mammifère et, en particulier, de composés réduisant la formation des peptides bêta-amyloïdes. L'invention concerne également des agents inhibiteurs ciblant la signalisation de la bêta-arrestine, des compositions pharmaceutiques les contenant et leur utilisation pour traiter lesdits troubles.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)